B-intervention	0	6	Breast
I-intervention	7	13	ductal
I-intervention	14	20	lavage
O	21	24	for
O	25	34	biomarker
O	35	45	assessment
O	46	48	in
O	49	53	high
O	54	58	risk
O	59	64	women
O	64	65	:
O	66	75	rationale
O	75	76	,
O	77	83	design
O	84	87	and
O	88	99	methodology
O	100	102	of
O	103	104	a
O	105	115	randomized
O	116	121	phase
O	122	124	II
O	125	133	clinical
O	134	139	trial
O	140	144	with
O	145	155	nimesulide
O	155	156	,
O	157	168	simvastatin
O	169	172	and
O	173	180	placebo
O	180	181	.

O	182	189	Despite
O	190	198	positive
O	199	206	results
O	207	211	from
O	212	217	large
O	218	223	phase
O	224	227	III
O	228	236	clinical
O	237	243	trials
O	244	250	proved
O	251	255	that
O	256	258	it
O	259	261	is
O	262	270	possible
O	271	273	to
O	274	281	prevent
O	282	290	estrogen
O	290	291	-
O	291	301	responsive
O	302	308	breast
O	309	316	cancers
O	317	321	with
O	322	331	selective
O	332	340	estrogen
O	341	349	receptor
O	350	360	modulators
O	361	364	and
O	365	374	aromatase
O	375	385	inhibitors
O	385	386	,
O	387	389	no
O	390	401	significant
O	402	409	results
O	410	414	have
O	415	419	been
O	420	427	reached
O	428	430	so
O	431	434	far
O	435	437	to
O	438	445	prevent
O	446	453	hormone
O	454	457	non
O	457	458	-
O	458	468	responsive
O	469	475	tumors
O	475	476	.

O	477	480	The
O	481	487	Ductal
O	488	494	Lavage
O	495	496	(
O	496	498	DL
O	498	499	)
O	500	509	procedure
O	510	516	offers
O	517	518	a
O	519	528	minimally
O	529	537	invasive
O	538	544	method
O	545	547	to
O	548	554	obtain
O	555	561	breast
O	562	572	epithelial
O	573	578	cells
O	579	583	from
O	584	587	the
O	588	594	ductal
O	595	601	system
O	602	605	for
O	606	620	cytopathologic
O	621	629	analysis
O	629	630	.

O	631	638	Several
O	639	646	studies
O	647	651	with
O	652	656	long
O	656	657	-
O	657	661	term
O	662	668	follow
O	668	669	-
O	669	671	up
O	672	676	have
O	677	682	shown
O	683	687	that
O	688	693	women
O	694	698	with
O	699	707	atypical
O	708	719	hyperplasia
O	720	724	have
O	725	727	an
O	728	736	elevated
O	737	741	risk
O	742	744	of
O	745	755	developing
O	756	762	breast
O	763	769	cancer
O	769	770	.

O	771	774	The
O	775	784	objective
O	785	787	of
O	788	791	the
O	792	800	proposed
O	801	806	trial
O	807	809	is
O	810	812	to
O	813	819	assess
O	820	823	the
O	824	832	efficacy
O	833	836	and
O	837	843	safety
O	844	846	of
O	847	848	a
O	849	854	daily
O	855	869	administration
O	870	872	of
O	873	883	nimesulide
O	884	886	or
O	887	898	simvastatin
O	899	901	in
O	902	907	women
O	908	910	at
O	911	917	higher
O	918	922	risk
O	923	926	for
O	927	933	breast
O	934	940	cancer
O	940	941	,
O	942	949	focused
O	950	962	particularly
O	963	965	on
O	966	973	hormone
O	974	977	non
O	977	978	-
O	978	988	responsive
O	989	994	tumor
O	995	999	risk
O	999	1000	.

O	1001	1004	The
O	1005	1012	primary
O	1013	1021	endpoint
O	1022	1024	is
O	1025	1028	the
B-outcome-Measure	1029	1035	change
I-outcome-Measure	1036	1038	in
I-outcome-Measure	1039	1049	prevalence
I-outcome-Measure	1050	1052	of
I-outcome-Measure	1053	1061	atypical
I-outcome-Measure	1062	1067	cells
I-outcome-Measure	1068	1071	and
I-outcome-Measure	1072	1076	cell
I-outcome-Measure	1077	1090	proliferation
O	1091	1092	(
O	1092	1100	measured
O	1101	1103	by
O	1104	1108	Ki67
O	1108	1109	)
O	1110	1112	in
O	1113	1115	DL
O	1116	1118	or
O	1119	1123	fine
O	1124	1130	needle
O	1131	1139	aspirate
O	1140	1147	samples
O	1147	1148	,
O	1149	1154	after
O	1155	1157	12
O	1158	1164	months
O	1165	1167	of
O	1168	1177	treatment
O	1178	1181	and
O	1182	1184	12
O	1185	1191	months
O	1192	1197	after
O	1198	1207	treatment
O	1208	1217	cessation
O	1217	1218	.

O	1219	1226	METHODS
O	1226	1227	-
O	1227	1233	DESIGN
O	1233	1234	:
O	1235	1239	From
O	1240	1244	2005
O	1245	1247	to
O	1248	1252	2011
O	1252	1253	,
B-total-participants	1254	1257	150
B-eligibility	1258	1263	women
I-eligibility	1264	1268	with
I-eligibility	1269	1270	a
I-eligibility	1271	1278	history
I-eligibility	1279	1281	of
I-eligibility	1282	1290	estrogen
I-eligibility	1291	1299	receptor
I-eligibility	1300	1308	negative
I-eligibility	1309	1315	ductal
I-eligibility	1316	1331	intraepithelial
I-eligibility	1332	1341	neoplasia
I-eligibility	1342	1344	or
I-eligibility	1345	1352	lobular
I-eligibility	1353	1368	intraepithelial
I-eligibility	1369	1378	neoplasia
I-eligibility	1379	1381	or
I-eligibility	1382	1390	atypical
I-eligibility	1391	1402	hyperplasia
I-eligibility	1402	1403	,
I-eligibility	1404	1406	or
I-eligibility	1407	1417	unaffected
I-eligibility	1418	1426	subjects
I-eligibility	1427	1435	carrying
I-eligibility	1436	1437	a
I-eligibility	1438	1446	mutation
I-eligibility	1447	1449	of
I-eligibility	1450	1455	BRCA1
I-eligibility	1456	1458	or
I-eligibility	1459	1463	with
I-eligibility	1464	1465	a
I-eligibility	1466	1477	probability
I-eligibility	1478	1480	of
I-eligibility	1481	1489	mutation
I-eligibility	1490	1491	>
I-eligibility	1491	1493	10
I-eligibility	1493	1494	%
I-eligibility	1495	1496	(
I-eligibility	1496	1505	according
I-eligibility	1506	1508	to
I-eligibility	1509	1516	BRCAPRO
I-eligibility	1516	1517	)
O	1518	1522	were
O	1523	1533	randomized
O	1534	1536	to
O	1537	1544	receive
O	1545	1555	nimesulide
O	1556	1561	100mg
O	1561	1562	/
O	1562	1565	day
O	1566	1572	versus
O	1573	1584	simvastatin
O	1585	1589	20mg
O	1589	1590	/
O	1590	1593	day
O	1594	1600	versus
B-control	1601	1608	placebo
O	1609	1612	for
O	1613	1616	one
O	1617	1621	year
O	1622	1630	followed
O	1631	1633	by
O	1634	1635	a
O	1636	1642	second
O	1643	1647	year
O	1648	1650	of
O	1651	1657	follow
O	1657	1658	-
O	1658	1660	up
O	1660	1661	.

O	1662	1666	This
O	1667	1669	is
O	1670	1673	the
O	1674	1679	first
O	1680	1690	randomized
O	1691	1698	placebo
O	1699	1709	controlled
O	1710	1715	trial
O	1716	1718	to
O	1719	1727	evaluate
O	1728	1731	the
O	1732	1736	role
O	1737	1739	of
O	1740	1742	DL
O	1743	1745	to
O	1746	1751	study
O	1752	1761	surrogate
O	1762	1771	endpoints
O	1772	1782	biomarkers
O	1783	1786	and
O	1787	1790	the
O	1791	1798	effects
O	1799	1801	of
O	1802	1807	these
O	1808	1813	drugs
O	1814	1816	on
O	1817	1823	breast
O	1824	1838	carcinogenesis
O	1838	1839	.

O	1840	1842	In
O	1843	1847	2007
O	1848	1851	the
O	1852	1860	European
O	1861	1870	Medicines
O	1871	1877	Agency
O	1878	1885	limited
O	1886	1889	the
O	1890	1893	use
O	1894	1896	of
O	1897	1905	systemic
O	1906	1918	formulations
O	1919	1921	of
O	1922	1932	nimesulide
O	1933	1935	to
O	1936	1938	15
O	1939	1943	days
O	1943	1944	.

O	1945	1954	According
O	1955	1957	to
O	1958	1961	the
O	1962	1970	European
O	1971	1980	Institute
O	1981	1983	of
O	1984	1992	Oncology
O	1993	1999	Ethics
O	2000	2009	Committee
O	2010	2023	communication
O	2023	2024	,
O	2025	2027	we
O	2028	2031	are
O	2032	2035	now
O	2036	2046	performing
O	2047	2049	an
O	2050	2054	even
O	2055	2059	more
O	2060	2067	careful
O	2068	2078	monitoring
O	2079	2081	of
O	2082	2085	the
O	2086	2091	study
O	2092	2104	participants
O	2104	2105	.

O	2106	2117	Preliminary
O	2118	2125	results
O	2126	2132	showed
O	2133	2137	that
B-outcome	2138	2140	DL
I-outcome	2141	2143	is
I-outcome	2144	2145	a
I-outcome	2146	2154	feasible
I-outcome	2155	2164	procedure
O	2164	2165	,
O	2166	2169	the
B-outcome	2170	2179	treatment
I-outcome	2180	2182	is
I-outcome	2183	2187	well
I-outcome	2188	2197	tolerated
O	2198	2201	and
O	2202	2205	the
O	2206	2212	safety
O	2213	2218	blood
O	2219	2224	tests
O	2225	2227	do
O	2228	2231	not
O	2232	2236	show
O	2237	2240	any
O	2241	2252	significant
B-outcome	2253	2258	liver
I-outcome	2259	2267	toxicity
O	2267	2268	.

O	2269	2274	There
O	2275	2277	is
O	2278	2280	an
O	2281	2287	urgent
O	2288	2292	need
O	2293	2295	to
O	2296	2303	confirm
O	2304	2306	in
O	2307	2310	the
O	2311	2319	clinical
O	2320	2327	setting
O	2328	2331	the
O	2332	2341	potential
O	2342	2350	efficacy
O	2351	2353	of
O	2354	2359	other
O	2360	2369	compounds
O	2370	2372	in
O	2373	2384	contrasting
O	2385	2392	hormone
O	2393	2396	non
O	2396	2397	-
O	2397	2407	responsive
O	2408	2414	breast
O	2415	2421	cancer
O	2421	2422	.

O	2423	2427	This
O	2428	2433	paper
O	2434	2436	is
O	2437	2444	focused
O	2445	2447	on
O	2448	2451	the
O	2452	2463	methodology
O	2464	2467	and
O	2468	2479	operational
O	2480	2487	aspects
O	2488	2490	of
O	2491	2494	the
O	2495	2503	clinical
O	2504	2509	trial
O	2509	2510	.

O	2511	2512	(
O	2512	2526	ClinicalTrials
O	2526	2527	.
O	2527	2530	gov
O	2531	2541	Identifier
O	2541	2542	:
O	2543	2554	NCT01500577
O	2554	2555	)
O	2555	2556	.
